For citations:
Mayevskaya M.V., Ivashkin V.T., Znoyko O.O., Klimova Ye.A., Abdurakhmanov D.T., Bakulin I.G., Bogomolov P.O., Burnevich E.Z., Galushko M.Yu., Geyvandova N.I., Zhdanov K.V., Esaulenko Ye.V., Kizhlo S.N., Konstantinov D.Yu., Mironova N.I., Morozov V.G., Strebkova Ye.A., Nikitin I.G., Osipenko M.F., Pasechnikov V.D., Sagalova O.I., Khayertynova I.M., Chulanov V.P., Yakovlev A.A., Vasyutin I.A., Tarkhova Ye.P., Krasavina E.N., Samsonov M.Yu. Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(6):41-51. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-6-41-51
Email this article 
